BMS-963272

BMS-963272 is a potent and selective small molecule inhibitor of monoacylglycerol O-acyltransferase 2 (MGAT2), developed by Bristol Myers Squibb as an oral therapy for metabolic disorders, including diabetes mellitus and non-alcoholic fatty liver disease (NAFLD). MGAT2 is an enzyme highly expressed in the human small intestine and liver, playing a key role in triglyceride absorption and homeostasis. In preclinical models, BMS-963272 reduced inflammation, fibrosis, hepatic steatosis, body weight, and improved relevant biomarkers. The drug was advanced to phase 1 clinical trials but development was terminated due to business reasons. Its mechanism of action involves inhibition of MGAT2 to modulate lipid metabolism and reduce metabolic dysfunction[3][5][6].